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ABSTRACT
Objectives: To determine whether allocation of resources
into further research of breast cancer screening is warranted;
also, to identify the parameters, for which the information
would be most valuable, to prioritize the further research if
deemed justiﬁable.
Methods: The Bayesian value of information analysis was
conducted to calculate the overall expected value of perfect
information (EVPI) and the partial EVPI for the six groups of
parameters. Computational expense of the partial EVPI cal-
culation was challenged with the use of Multiple Linear
Regression and Gaussian Process metamodels to signiﬁcantly
cut down the computing time.
Results: Of the two metamodeling techniques, the Gaussian
Process was proven to perform superiorly and was therefore
chosen for the partial EVPI calculation. The results indicate a
considerable range in the population EVPI estimates, between
€100 and €500 millions at the willingness-to-pay values
between €10,000 and €40,000 per quality-adjusted life-year.
The partial EVPI for the groups of parameters indicated that
future research would be most valuable if directed toward
obtaining more precise estimates of the cancer sojourn times.
With the use of the Gaussian process metamodels, the com-
puting time was reduced from 44 years to 47 days.
Conclusions: Although the large values of EVPI suggest col-
lection of further information before choosing the screening
policy, it is argued that delaying the decision would result in
signiﬁcantly higher opportunity loss. Therefore, the best
option would be to implement the most cost-effective policy
given the existing information (screening women aged
40–80 years, at 3-year intervals) and simultaneously conduct
observational studies alongside the implemented policy. The
decision analytic model could be in this manner periodically
updated with additional information as it became available
and the most cost-effective policy chosen iteratively.
Keywords: Bayesian value of information analysis, breast
cancer screening, Gaussian process, metamodel, partial EVPI.
Introduction
The decisions about cost-effectiveness of new interven-
tions in health care are inevitably taken under condi-
tions of uncertainty. Given that the decision on the
basis of existing intervention is uncertain, there is
always a chance that the wrong decision has been
made [1]. As a result, the costs in terms of health
beneﬁts and resources are forgone. Therefore, the eco-
nomic analysis should also evaluate whether the gath-
ering of additional information is warranted [2]. The
expected costs of uncertainty can be interpreted as the
expected value of perfect information (EVPI), because
perfect information eliminates the possibility of
making the wrong decision. This is also the maximum
that the health-care system should be willing to pay for
the additional evidence to inform this decision in the
future, and it places an upper bound on the value of
conducting further research [3].
The EVPI is determined by the probability that a
decision is wrong and by the size of the opportunity
loss. The overall EVPI of the model is the difference
between the expected net beneﬁts of the optimum deci-
sion when all information is known and the expected
net beneﬁts of the optimum decision with no addi-
tional information. It can be written as:
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where q are the parameters for the model with
deﬁned prior probability distributions, d is the set of
possible decisions and NB(d, q) is the function of net
beneﬁts for the decision d, and the parameters q [4].
Likewise, the expected value of learning the true
value of an individual parameter or the true values of
a subset of the parameters can be acquired. The
partial EVPI for a subset of parameters can be
written as:
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where qi are the parameters of interest for the partial
EVPI [4]. The partial EVPI for the parameters qi is the
difference between the expected net beneﬁts of the
optimum decision when only information regarding qi
is known and the expected net beneﬁts of the optimum
decision with no additional information.
Methods of Partial EVPI Calculation for
Complex Models
Monte Carlo method can be used to evaluate the above
given expectations in EVPI calculation. The simplicity
of the method has its price in the running time of the
calculation, especially for the partial EVPI, where the
two-level sampling must be used to evaluate the double
expectation. Supposedly, if a model needed only 1 s per
model simulation, and if the sample sizes of 1000
simulations for the inner and 1000 simulations for the
outer expectation estimates were required, the running
time would be approximately 11.6 days for only one
set of parameter(s). With more complex models that
have longer running times and need more samples to
evaluate expectations, the time for value of informa-
tion (VOI) analysis would become unacceptable,
because it would be measured in years. To overcome
this problem, the use of metamodels as a replacement
for the original simulation models has been suggested
[5]. Metamodels are effectively “models of models,” or
mathematical approximations to the input and output
functions of the model. They are intended to provide a
good approximation of the model while signiﬁcantly
cutting down the necessary computing time [4].
The relationship between the input parameters x
and the output y of the simulation model can be
written as y = f(x). Metamodeling attempts to approxi-
mate the function f that relates the inputs ¥ with the
output y by deﬁning a separate function h, where h
must approximate the f with sufﬁcient precision, that
is, f(x) ª (x). In practice, this is done by running the
original model f(x) on a moderate number of training
input values, constructing the approximation function
h(x) and ﬁnally using the function h(x) for further
simulations. In the present work, the functions h(x)
were constructed and validated with either Multiple
Linear Regression (MLR) or Gaussian process (GP)
metamodels. Then, according to their accuracy and
time reduction, the more appropriate method was
chosen for partial EVPI calculation.
Because the intention of the article is to present a
case study of the GP metamodeling technique and not
the overview of the method, please refer to Tappenden
et al. [4] for a systematic review and critical appraisal
of metamodeling techniques, including Multiple
Linear Regression, neural networks, response surfaces,
regression splines, and Gaussian processes. Some other
case studies of the GP promising performance in com-
parison to other metamodeling techniques can also be
found in the literature [6,7].
Gaussian process regression is a Bayesian nonpara-
metric method that is particularly appropriate in cases
where the simulation model under consideration is
highly nonlinear and there is uncertainty regarding the
true functional form of the model [4]. Like many other
metamodeling techniques, the GP assumes that the
output function f is fairly smooth, so that if the value
of the output is known for particular input parameters,
then the estimate of the output can be made for input
parameters close to x. The accuracy of the GP model
will be the highest around the training input data
points, on which the model was ﬁtted and will decrease
for the values of input parameters, which are further
away from the training data points. Therefore, a deci-
sive factor for the metamodel’s performance is also the
selection of the training input data points.
The statistical theory with the mathematical details
of the GP can be found in Kennedy and O’Hagan [8]
and Oakley and O’Hagan [9,10]. The ﬁrst application
of a GP emulator for health economic model was by
Stevenson et al. [7]. A more introductory tutorial on
Bayesian Analysis of the computer code with the GP
can be found in O’Hagan [11].
Objective
In a recently published article [12], a probabilistic
model of different mammography breast cancer
screening policies has been presented and the cost-
effectiveness analysis of 36 different screening policies
relative to no-screening policy has been performed.
The present article presents an upgrade of the previous
work and supplements the decision-making process of
adopting an appropriate screening policy. The objec-
tive of the presented work was to determine whether
allocation of resources into further research of breast
cancer screening in Slovenia is warranted. Also, the
identiﬁcation of the parameters, for which the infor-
mation would be most valuable, was performed to
prioritize the further research if deemed justiﬁable.
This was accomplished by using the Bayesian VOI
approach.
The methods for estimating overall EVPI and EVPI
associated with parameters are now well established.
Nevertheless, there are computational challenges for
complex models, which need to be addressed [13].
Although the above mentioned model for breast cancer
screening used a cohort-based approach to model the
patient history, it still had a running time in the order of
2–3 min per 1 simulation of 36 different screening
policies and no-screen policy. The potential conﬂict
between the computationally expensive model and the
partial EVPI analysis, which requires a large amount of
simulations, was resolved with the use of the metamod-
els [14]. The methodological framework for the EVPI
analysis for computationally expensive health eco-
nomic models was followed as proposed by Tappenden
et al. [4]. This approach allowed a comprehensive EVPI
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analysis in a timely manner with sufﬁcient accuracy.
Although the GP methodology reportedly requires
greater specialist expertise in contrast to theMLR [4], it
is our opinion that the availability of the computer
software for this purpose facilitates its use also by
analysts with average statistical and programming
skills.
Methods
Model Description
The objective of the decision analytic model was to
explore the cost-effectiveness of the population-based
mammography breast cancer screening in Slovenia,
and to choose the most favorable screening policy. A
total of 36 screening policies, which differed in the age
eligibility criteria and in the screening interval, and
no-screening policy were taken into consideration. A
time-dependent Markov model was build to compare
hypothetic populations of women, one followed clini-
cally without screening and the others undergoing dif-
ferent screening mammography policies (Fig. 1). The
model characterized the natural history of the disease
as having four preclinical stages (DCIS, local, regional,
and distant breast cancer) when cancer shows no clini-
cal symptoms. The preclinical stage breast cancer can
either progress to more invasive preclinical stages,
it can progress to clinically detected stages (local,
regional, and distant clinical stages), or it can be
detected with mammography in the presence of screen-
ing (DCIS, local, regional, and distant screen-detected
stages). The state “false positives” referred to women
with the positive screening examination in whom no
breast cancer is found at further invasive assessment.
The two absorbing end-states of the model were death
from breast cancer and death from other causes.
Various patterns of stage speciﬁc treatments were
assigned to different clinically and screen detected
stages of breast cancer. Treatments consisted of four
basic interventions: surgery, hormonal therapy, radio-
therapy, and chemotherapy. Beside the treatment costs,
the model included also the costs of diagnostic proce-
dures: the cost of mammography examination, the
costs for diagnostic interventions for clinically detected
breast cancer, and the costs for invasive and noninva-
sive diagnostics at recall.
The beneﬁts of breast cancer screening arise from
more favorable prognosis associated with the identiﬁ-
cation and the treatment of cancer at earlier stages,
thus effectively preventing the premature mortality and
morbidity. On the other hand, the unnecessary workup
in population with false positives and overdiagnosis of
the DCIS of the DCIS represent the negative aspect of
the breast cancer screening. Effectiveness of different
policies was measured in terms of quality-adjusted life-
years (QALYs). In each of the modeled cancer states
and in the false positive state, QALY weights were
assigned according to the treatment intervention and
according to the diagnostic procedures.
Uncertainty in the model was represented by the
cost-effectiveness acceptability curves and the cost-
effectiveness acceptability frontier (Fig. 2). The curves
demonstrated that although screening was potentially
cost-effective at l-values higher than €4000 per QALY,
there was signiﬁcant uncertainty surrounding the cost-
effectiveness of the screening strategies on the frontier.
Although this uncertainty is considered irrelevant to
the adoption decision within the proposed framework,
it has signiﬁcant implications for the value of conduct-
ing further research to support this decision [15].
Full description of the model and the results can be
found in Rojnik et al. [12].
Selection of Relevant Policies
To (further) reduce the computer running time for the
VOI analysis, the treatment policies that are never the
most cost-effective can be excluded. Because the EVPI is
a function of the maximums of net beneﬁts, the simu-
lation of policies that are never the most cost-effective
is unnecessary for EVPI calculation. Therefore, the
No breast
cancer
False
positive
Screening
Local Local
Local
DCIS
DCIS
Regional Regional
Regional Death form
breast cancer
Distant Distant
Distant
Perclinical screen-detectable breast cancer
Screen-detected breast cancer
Clinically diagnosed
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Figure 1 The structure of the model for the
breast cancer screening with indicated possible
courses of the disease.The dashed lines corre-
spond to transitions possible only by screening
policies. The state “death from other causes,”
which can be attained from all other states, is
not shown.
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policies with probability of being cost-effective lower
than 0.5% at any value of willingness to pay per QALY
(l) were excluded fromVOI analysis. Of the starting 37
policies (no screening policy and 36 different screening
policies), only 12 remained (no screening policy and 11
different screening policies), which are presented in
Table 1 along with their expected costs, their expected
QALYs and their incremental cost-effectiveness ratios
(ICER).
Multiple Linear Regression and GP Metamodels
The process of applying the MLR and the GP meta-
modeling methodology in the partial EVPI analysis
consisted of ﬁve steps:
• selection of the training input data points,
• calculation of the model outputs (costs and
QALYs) from the training input data points with
the original model,
• ﬁtting the MLR or the GP metamodels on the
training input data points and calculated model
outputs,
• validation of the MLR and the GP metamodels,
• prediction of the outputs from the simulated input
data points for EVPI calculation.
The software used for the selection of input data
points and ﬁtting of GP metamodels was Gaussian
Emulation Machine for Sensitivity Analysis (GEM-
SA), which has been developed by Marc Kennedy [16].
The GEM-SA can currently ﬁt models with a
maximum of 30 input parameters, hence the costs and
the QALYs were modeled separately, as the net beneﬁts
of the screening policies were a function of 38 different
input parameters. The costs were a function of 28
input variables and the QALYs were a function of 30
variables, with both having 20 common input vari-
ables. Maximin Latin hypercube algorithm was used in
the GEM-SA to generate 400 training input data
points for the costs models and 400 training input data
points for the QALYs models, which is the maximum
number of the training inputs currently allowed by the
GEM-SA. This algorithm has good space-ﬁlling prop-
erties and should therefore result in an efﬁcient emu-
lator. The limits of the training input data points were
deﬁned as the theoretical 0.1 and 99.9 percentiles of
the input parameter distributions. Likewise, these
limits were used for 10,000 training input data points
for MLR metamodels. Because the MLR method
requires less time for construction of models than the
GP, a larger number of uniformly distributed training
input data points were chosen to efﬁciently cover the
input parameter space for the MLR metamodels.
The original model for breast cancer screening was
then used to estimate the costs and the QALYs for
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Figure 2 The cost-effectiveness acceptability
curves (gray lines) with the cost-effectiveness
acceptability frontier (bold black line). Descrip-
tion of the screening policies is given in the
Table 1. QALY, quality-adjusted life-year.
Table 1 The screening policies taken into consideration, their labeling in the article with the expected costs and the expected
quality-adjusted life-years (QALYs) and the corresponding incremental cost-effectiveness ratios (ICER)
Label 0 15 16 25 26 27 28 29 30 31 33 34
Screening period (age, years) No screening 40–75 40–80 40–65 40–70 40–75 40–80 45–65 45–70 45–75 50–65 40–70
Interval (years) 2 2 3 3 3 3 3 3 3 3 3
Expected QALY 22.973 23.045 23.047 23.033 23.039 23.040 23.042 23.022 23.028 23.031 23.011 23.014
Expected costs (€) 284.1 798.4 826.3 572.8 602.9 614.8 633.1 491.5 523.1 546.6 435.6 451.2
ICER D 40,294 D 7,290 7,704 11,897 5,120 5,355 D 4,042 D
Dominated policies are labeled with D.
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different screening policies at the generated training
input data points. The inputs and the outputs for theGP
metamodels were imported in the GEM-SA program,
which was used to ﬁt all 24 GP metamodels for 12
screening policies. Each ﬁtting took approximately 3 h
of computing time on the Pentium IV 3.0 GHz com-
puter. Fitting time for each of the 24 MLR metamodels
in the sas System for Windows v8.2 [17] was approxi-
mately 1 min. The models included all ﬁrst-order inter-
actions between the input parameters, thus making
them 495 parameter metamodels for the QALYs and
434 parameter metamodels for the costs. The building
of separate metamodels for the costs and the QALYs in
both metamodeling approaches proved beneﬁcial, as
the results of VOI analysis were then easily presented as
a function of the willingness to pay per QALY.
The GEM-SA program is not capable of predicting
a large number of points, so the simulation of the costs
and the QALYs for the EVPI calculation was done with
the sas System for Windows v8.2 [17]. This step could
also be done with the R program [18], for which the
functions are made available by J. Oakley on the pages
of Center for Bayesian Statistics in Health Economics,
University of Shefﬁeld [19].
Validations of the MLR and the GP metamodels
were performed with the results of the original model
for breast cancer screening. All 10,000 input points
from the original probabilistic sensitivity analysis were
used to predict the costs and the QALYs of 12 different
screening policies, once with the MLR metamodels
and once with the GP metamodels. The predictions of
the costs and the QALYs were then compared with
the observed values of the costs and the QALYs and
graphically presented as scatter plots. To determine the
accuracy of the metamodels at predicting mean values,
the predicted expected costs and the predicted
expected QALYs along with the predicted expected net
beneﬁts for a range of l-values were compared with
the observed values. Additionally, the ability to accu-
rately predict the extreme values of model outputs,
from which the EVPI is calculated, was veriﬁed by
comparing the observed overall EVPI of the original
model and the overall EVPI predicted by the MLR and
the GP metamodels.
After the validation of the MLR and the GP meta-
models, the more appropriate method regarding the
accuracy and the time reduction was chosen for the
partial EVPI calculation. The partial EVPI were calcu-
lated for the six groups of parameters (costs, QALYs,
screening characteristics, sojourn times, clinical stage
distribution and survival). The parameters were
grouped by their relationship and the connectedness at
their acquirement.
Sample Sizes for the EVPI Calculation
When using the two-level Monte Carlo algorithm to
estimate the partial EVPI, it is necessary to determine
how many samples are needed for an accurate assess-
ment of the inner and the outer expectations. A too
small inner sample will produce a bias in the partial
EVPI estimate and a too small outer sample will
produce wide conﬁdence intervals in the partial EVPI
estimate. Here the algorithm as proposed by Tap-
penden et al. [4] was used for determining the sufﬁ-
cient sample sizes for estimating the inner and outer
level expectations.
Calculation of the EVPI
The step-by-step algorithms that were used for the
calculation of the overall and the partial EVPI are
given bellow [4].
For the overall EVPI:
• The probabilistic uncertainty analysis was per-
formed for all uncertain parameters and the net
beneﬁts for each iteration were recorded [12].
• For each simulation of the model, the difference
between the maximum net beneﬁt across all treat-
ment policies and the maximum of the average net
beneﬁts across all treatment policies (e.g., NB of
the policy of choice) was calculated.
• The overall EVPI was obtained by computing the
average of the differences calculated in the previ-
ous step.
For the partial EVPI:
• Parameters of interest (qi) were sampled once from
their prior distributions and were held ﬁxed at
their sampled values. All other model parameters
(qc) were let to vary according to their prior uncer-
tainty (inner-level simulations). The maximum of
the average net beneﬁts across all treatment policy
was recorded.
• The previous step was repeated many times (outer-
level simulations) and the average of the maxi-
mums calculated in the previous step was
calculated.
• The partial EVPI was obtained by computing the
difference between value calculated in previous
step and the maximum of the average net beneﬁts
across all treatment policies (e.g., NB of the policy
of choice).
The above stated algorithms provided the per
patient values of EVPI. To calculate the population
values of EVPI, a 10-year lifetime of decision was
assumed and the annual EVPI was discounted at 3%.
The number of women in Slovenia older than 40 years
is approximately 520,000 and it has been rising for the
last 10 years at a constant rate of 1.2% per year [20].
Therefore, the growth of population has been included
in the calculation of population EVPI. The population
EVPI over an assumed decision lifetime was calculated
with the following equation [15]:
244 Rojnik and Naveršnik
Population EVPI EVPI= ⋅
⋅ +( )
+( )=∑
P pg
r
i
i
i
L 1
11
(3)
where P is the current number of eligible women, r is
the discount rate, pg is the annual population growth
and L is the effective life-time of the intervention.
Results
The Accuracy of the Multiple Linear Regression and the
GP Metamodels
The accuracy of the MLR and the GP metamodels for
the costs and the QALYs was estimated by predicting
the 10,000 simulation runs from the original probabi-
listic sensitivity analysis with the MLR and the GP
metamodels. The scatter plots of the predicted versus
observed values for the costs and the QALYs are pre-
sented in Figures 3 and 4 for the MLR metamodels,
and in Figures 5 and 6 for the GP metamodels. The
ﬁgures clearly indicate that both methods predicted the
QALYs better than the costs and that the MLR meta-
models for the costs may be inappropriate for further
simulation. The mean errors of the MLR metamodels
(deﬁned as the absolute difference between the pre-
dicted output and the true output divided by the range
of the true output) were between 1.9% and 6.0% for
the costs and between 0.4% and 1.2% for the QALYs.
The mean errors of the GP metamodels were between
0.5% and 1.1% for the costs and between 0.4% and
1.1% for the QALYs. Indication, that both methods
produced better predictions for the QALYs was
evident also from the Pearson’s R2 values between the
predicted and the observed outputs, which were
around 0.997 (MLR) and 0.996 (GP) for the QALYs
and around 0.728 (MLR) and 0.957 (GP) for the costs.
The distributions of errors were approximately sym-
metrical around 0 in all metamodels except in the
MLR metamodels for costs. The latter underestimated
the observed expected values by 8% to 16%. In con-
trast, the GP metamodels for the costs produced dif-
ferences between the predicted and the observed
expected values that were lower than 1% of their
observed expected values. Both approaches predicted
the expected values for QALYs extremely well, because
the differences were lower than 0.02% of their
observed expected value. The expected net beneﬁts
of different policies were ﬁtted accurately by both
approaches because the differences between the pre-
dicted and the observed expected values over the
studied range of l were lower than 0.94% of their
observed expected value for the MLR metamodels,
and lower than 0.08% for the GP metamodels. The
ability to accurately predict the extreme values of the
Figure 3 The scatter plot of 10,000 original versus the Multiple Linear
Regression metamodel-predicted cost values.
Figure 4 The scatter plot of 10,000 original versus the Multiple Linear
Regression metamodel-predicted quality-adjusted life-year (QALY) values.
Figure 5 The scatter plot of 10,000 original versus the Gaussian process
metamodel-predicted cost values.
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model outputs, from which the EVPI is calculated, was
investigated by comparing the observed and the pre-
dicted overall EVPI. The comparison, shown on
Figure 7, suggests that the GP metamodels predict the
extreme values of model outputs with sufﬁcient accu-
racy, whereas the MLR metamodels lack the accuracy
of the GP metamodels.
Overall, the accuracy of the MLR metamodels was
deemed inappropriate, especially due to poor predic-
tion of costs. Therefore, the simulations for the partial
EVPI calculation were performed with the GP meta-
models.
The original model for breast cancer screening fea-
tured correlations between outputs, either between
QALYs or costs of different screening policies. Because
of the fact, that the outputs were calculated from the
same input parameters and because the screening poli-
cies differed only in the number of screenings and in
the women’s ages at screening, the results of the origi-
nal probabilistic analysis showed very high correla-
tions among the QALYs and among the costs and
lower correlations between the costs and the QALYs.
Because the predictions of costs and QALYs with
metamodels for all 12 screening policies were per-
formed from the same input parameters (with the costs
and the QALYs having 20 in common), this correlation
pattern has been preserved with the metamodeling
despite the fact that separate metamodels were used
for each output.
Value of Information Analysis
The overall EVPI, presented on Figure 8, suggested
that the acquisition of further data may be justiﬁed.
When the l for cost-effectiveness is low (e.g., <€5000
per QALY), screening is not considered to be cost-
effective and additional information is unlikely to
change this decision. Consequently, the estimates of
EVPI are low. For l-values between €5000 and
Figure 6 The scatter plot of 10,000 original versus the Gaussian process
metamodel-predicted quality-adjusted life-year (QALY) values.
Figure 7 The observed,Multiple Linear Regression (MLR) and Gaussian process (GP) metamodel-predicted overall expected value of perfect information
(EVPI), presented in per patient and population values. QALY, quality-adjusted life-year.
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€10,000 per QALY there is signiﬁcant uncertainty over
which screening strategy is cost-effective, hence the
EVPI estimate is higher in this range. As the l rises
from €10,000 to €20,000 per QALY, then screening
policies 27 and 28 appear cost-effective and the lower
probability of incurring the opportunity losses offsets
the higher valuation of health outcome. When the l is
higher (e.g., over €40,000 per QALY) screening policy
16 is expected to be cost-effective and the higher valu-
ation of health outcome prevails over the lower prob-
ability of incurring opportunity losses, so the EVPI
increases. The high value of the overall population
EVPI is the consequence of a high EVPI per single
woman and because of the large number of women,
who could potentially beneﬁt from additional research
over the lifetime of the intervention.
The sample sizes for the inner and the outer level
expectations estimates in the partial EVPI analysis
were calculated with the algorithm proposed by Tap-
penden et al. [4]. The procedure was repeated for all
groups of parameters at several values of l and showed
that an inner sample size of 500 runs produced negli-
gible mean biases. The adequateness of relatively small
number of inner sample size runs can be explained by
a high correlation between the net beneﬁts of different
policies. Because the screening policies differ only in
the number of screenings and the patients’ ages at
screenings, the costs and QALYs are highly correlated
when calculated from the same input parameters. On
the contrary, the outer sample sizes smaller than 1000
produced fairly wide conﬁdence intervals of EVPI esti-
mates, indicating that a larger outer sample size will be
required. An outer level sample size of 10,000 runs
was considered appropriate, because larger sample
sizes would not considerably narrowed conﬁdence
intervals.
The results of the partial EVPI analysis for the six
groups of parameters are shown on Figure 8. They
indicate that at the l-values higher than €15,000, the
decision uncertainty would be lowered by most if
knowing the true values of the cancer sojourn times.
The EVPI for the other groups of parameters at l
higher than €25,000 are lower because they range
from 15% to 25% of the EVPI for sojourn times. At
l-values lower than €15,000, the EVPI values are
roughly the same for all groups with the EVPI values
for sojourn times being the lowest.
Time Reduction
The EVPI analysis with the sample sizes of 500 inner
and 10,000 outer level simulations took approxi-
mately 186 computational hours per parameter group
with the GP metamodels. The analysis for all six
parameter groups used approximately 47 computa-
tional days and was performed on several computers,
hence shortening the analysis time to under a week and
a half. When compared with the original model, this
presents only 0.3% of the expected computational
time of the original model (44 years) for the same EVPI
analysis. If the MLR metamodeling technique had
been employed, the time reduction would be even
Figure 8 The overall expected value of perfect information (EVPI) and the partial EVPI for the six groups of parameters, presented in per patient and
population values. QALY, quality-adjusted life-year.
GP Metamodeling in Bayesian VOI Analysis 247
larger, because the complete partial EVPI analysis with
the six parameter groups would use approximately 5.6
computational days.
Discussion
Value of Information Analysis
In the process of adopting a new intervention and
relocating health-care resources, sufﬁciency of current
evidence should also be considered. Based on the con-
sequences of the decision uncertainty, the decision
to conduct further research to support adoption, or
rejection, should be made simultaneously [3]. The pre-
sented Bayesian VOI analysis of breast cancer screen-
ing was undertaken to quantify the value of the
decision uncertainty consequences and to determine
the maximum value that can be placed on additional
research aimed at reducing this uncertainty. The esti-
mates of the EVPI provide an upper bound on the
value of additional research and provide a necessary
hurdle for determining the potential efﬁciency of
further primary research. This analysis can therefore
be used as the basis to inform policy decisions relating
to the future research priorities and study design issues
in this area.
Because there are some methodological issues
regarding the calculation of the population EVPI, the
results of the EVPI analysis are shown in both forms,
per woman and for whole population of women older
than 40 years over an assumed 10 years lifetime. For
now it is not clear how to incorporate the uncertainty
regarding the women population and the uncertainty
regarding the assumed effective lifetime of the inter-
ventions into the VOI analysis. Because this is an area
of further research, higher transparency of results was
achieved by presenting the EVPI per woman and for
whole population.
The population EVPI ranged from approximately
€100 to €500 millions at the l-values between €10,000
and €40,000 per QALY, indicating that further
research is warranted. The partial EVPI associated
with the cancer sojourn times is particularly high and
appears to account for the majority of uncertainty
surrounding the model. Other parameters appear to
have less important inﬂuence on the overall decision
uncertainty. Results from the model suggest that the
cancer sojourn times should have the highest priority
for future research aimed at further deﬁning the poten-
tial cost-effectiveness of breast cancer screening and
choosing the most cost-effective policy.
Although the results of VOI analysis clearly warrant
further research, the manner in which relevant infor-
mation could be obtained is less evident. Because the
majority of the input parameters can only be studied in
the screening program, the ﬁrst obvious option is to
organize a pilot study of mammography breast cancer
screening and emphasize the collection of data, which
would lower the decision uncertainty by most (cancer
sojourn times). But this approach has several draw-
backs. The incidence of breast cancer is relatively low,
so a large sample size should most likely be taken from
a relatively small Slovenian population. Also, the
estimation of some parameters (sojourn times, sur-
vival. . .) would be possible only after a long period,
which would move the ﬁnal decision regarding the
most cost-effective screening policy further into future.
Because all candidate policies for policy of choice in l
range between €10,000 and €40,000 per QALY (poli-
cies 26, 27, 28, 30, and 16) are more cost-effective
than the current no-screening policy, the delay in the
decision to adopt one of those policies would result in
forgone health beneﬁts. For example, if the decision is
delayed for 5 years to gather more information and the
current policy of no screening would remain, oppor-
tunity loss for not implementing screening policy 28 in
terms of health beneﬁts forgone would be from
approximately €800 to €5400 millions at l-values
between €10,000 and €40,000 per QALY.
Therefore, the better option would be to implement
the most cost-effective policy (screening policy 28) and
simultaneously conduct observational studies for
parameters of most interest alongside the implemented
policy. In this manner, the decision analytic model
could be periodically updated with additional informa-
tion as it became available and re-evaluated. If the new
evidence would suggest that some other policy is the
most cost-effective, the implementation of new policy
would not present major difﬁculties, because the poli-
cies differ only in the age eligibility and in the screening
frequencies.
Gaussian Process Metamodeling
In the process of the VOI analysis, the conﬂict between
the computationally expensive model and the partial
EVPI analysis was solved by using the GP metamod-
eling technique. Although the calculations of the
partial EVPI took approximately 47 computational
days, the task was achievable in a fairly reasonable
time frame, because the analysis time was further
reduced by using several computers. Clearly, the same
VOI analysis with the original model would be infea-
sible, because it would require 44 years to complete.
During the metamodeling process, the MLR tech-
nique was also tested for suitability. Although the
QALYs were ﬁtted comparably to GP metamodels, the
method clearly lacked the ability to predict highly non-
linear costs, despite the large number of the training
input points used (10,000). Therefore, the method was
deemed inappropriate, even though the analysis time
would have been only approximately 12% of the
analysis time with the GP metamodels.
The VOI analysis time with the GP metamodeling
could be additionally reduced at the expense of accu-
racy. Because the prediction time is heavily dependent
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on the number of training points for the GP meta-
models, time could be saved by building the GP meta-
models on fewer training points. But further research
would be required to ascertain the relationship
between the number of training points and the accu-
racy of the GP metamodels. Time reduction could also
be achieved by using a combination of Simpson’s rule
and Bayesian quadrature [6] for calculation of the
partial EVPI after the GP metamodel building. Never-
theless, this approach is limited on GP metamodeling
of the net beneﬁts and can be applied only for a single
parameter EVPI estimates. The implementation of this
approach would also require considerable specialist
programming and statistical expertise.
Although the GP method presents a powerful tool
for predicting the outputs from computationally
expensive models, it has several drawbacks. Beside the
complexity of the method, it has limited use for the
models with the large number of input parameters.
Currently, only 30 input parameters are supported in
the GEM-SA software, which would present a problem
if the GP metamodels would be ﬁtted on the net ben-
eﬁts of the presented model. Nevertheless, this can be
resolved by using the importance analysis techniques
to rank the parameters according to their importance
in the model and then omitting the less important ones
from the GP metamodel [4].
Another proposed solution for estimation of partial
EVPI for computationally expensive models is a one-
level Monte Carlo method [4]. If the net beneﬁts are
linear in each individual parameter and probabilisti-
cally independent, the inner expectation can be
replaced by the obtained net beneﬁt when qc are ﬁxed
at their prior means. The outer level expectation is
then estimated with the Monte Carlo integration (i.e.,
by 10,000 runs). Although the performed VOI analysis
for the six groups of parameters with this one-way
algorithm and the original probabilistic model would
require an expected time of 32 days, which is approxi-
mately 70% of time used by the GP metamodels, the
results would be questionable, because the presented
model is highly nonlinear.
Conclusions
With the presented approach, the conﬂict between
the computationally expensive health economic
models and the comprehensive VOI analysis was suc-
cessfully resolved. The use of the GP metamodeling
technique allowed the calculation of the partial EVPI
in a still acceptable time frame and was proven to
perform superiorly in comparison to the MLR meta-
modeling technique. The population EVPI estimates
suggest that further research in the area of breast
cancer screening is expected to be of signiﬁcant value.
The results indicate a considerable range in the popu-
lation EVPI estimates, between €100 and €500 mil-
lions at the l-values between €10,000 and €40,000
per QALY. Further primary research would appear to
be worthwhile given the large cost of uncertainty.
Partial EVPI for the groups of parameters indicated
that the future research would be most valuable if
directed toward obtaining more precise estimates of
the cancer sojourn times.
Although the large values of the EVPI suggest the
collection of further information before choosing the
screening policy, the characteristics of the information
acquirement (e.g., cancer sojourn times) make the
option of delaying the decision irrational. Because the
results of this additional research would only be avail-
able after a long time, a delay in the decision would
present signiﬁcant health beneﬁts forgone that would
be much higher than the EVPI. This is because the
current no-screening policy is less cost-effective than
the candidates for the policy of choice at selected
l-values. Therefore, the best option would be to imple-
ment the most cost-effective policy given the existing
information (screening women aged 40–80 years, at a
3-year interval) and simultaneously conduct observa-
tional studies for parameters of most interest alongside
the implemented policy. The decision analytic model
could be in this manner periodically updated with
additional information as it became available and the
most cost-effective policy chosen iteratively.
The presented approach of using the metamodels in
the VOI analysis also increases the accessibility of the
extensive VOI analysis for computationally expensive
health economic models and additionally rejects the
computational expense as the reason for omission of
such analysis.
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